ARRAY-162-311: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas
Female Reproductive Cancer
This is a clinical trial of MEK162 that will be administered by mouth which is investigational or either liposomal doxorubicin, paclitaxel, or topotecan that will be administered by IV and are standard of care.
IRB Protocol #
Array BioPharma, Inc
REBECCA KISSANE at (720)848-7202 or REBECCA.KISSANE@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last until study doctor determines it must be discontinued for safety reasons. A follow up period for remaining lifetime will consist of clinic visits every 12 weeks for tumor assessments. // Eligibility criteria include but are not limited to 18 years or older with cancer of the ovary, fallopian tube, or primary peritoneum.Eligibility criteria include but are not limited to 18 years or older with cancer of the ovary, fallopian tube, or primary peritoneum.